All In Biotech

Drug Trial Radar · NCT06079398

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jan 23, 2024

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.

Conditions

  • Achondroplasia

Interventions

  • NavepegritideDrug

    Once-weekly subcutaneous injection of 100 µg/kg Navepegritide

  • Placebo for NavepegritideDrug

    Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of NavepegritideTime frame: 52 weeks
  2. To evaluate the effect of Navepegritide on growthTime frame: 52 weeks

Locations

18 sites in 15 countries. Site status is shown where the registry gives one.

  • Ascendis Investigational Site

    Saint Paul, Minnesota · Recruiting

  • Ascendis Investigational Site

    Houston, Texas · Recruiting

  • Ascendis Investigational Site

    Madison, Wisconsin · Recruiting

  • Ascendis Investigational Site

    Parkville, Australia · Recruiting

  • Ascendis Investigational Site

    Linz, Austria · Recruiting

  • Ascendis Investigational Site

    Montreal, Canada · Recruiting

  • Ascendis Investigational Site

    Copenhagen, Denmark · Recruiting

  • Ascendis Investigational Site

    Helsinki, Finland · Recruiting

  • Ascendis Investigational Site

    Paris, France · Recruiting

  • Ascendis Investigational Site

    Berlin, Germany · Recruiting

  • Ascendis Investigational Site

    Cologne, Germany · Recruiting

  • Ascendis Investigational Site

    Dublin, Ireland · Recruiting

  • Ascendis Investigational Site

    Milan, Italy · Recruiting

  • Ascendis Investigational Site

    Auckland, New Zealand · Recruiting

  • Ascendis Investigational Site

    Oslo, Norway · Recruiting

  • Ascendis Investigational Site

    Coimbra, Portugal · Recruiting

  • Ascendis Investigational Site

    Stockholm, Sweden · Recruiting

  • Ascendis Investigational Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.